- Home
- DSP vs STTK Comparison
DSP vs STTK Comparison
Compare DSP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- STTK
- Stock Information
- Founded
- DSP 1999
- STTK 2016
- Country
- DSP United States
- STTK United States
- Employees
- DSP N/A
- STTK N/A
- Industry
- DSP EDP Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- STTK Health Care
- Exchange
- DSP Nasdaq
- STTK Nasdaq
- Market Cap
- DSP 220.3M
- STTK 37.6M
- IPO Year
- DSP 2021
- STTK 2020
- Fundamental
- Price
- DSP $13.31
- STTK $0.85
- Analyst Decision
- DSP Strong Buy
- STTK Hold
- Analyst Count
- DSP 8
- STTK 4
- Target Price
- DSP $21.75
- STTK $3.00
- AVG Volume (30 Days)
- DSP 248.3K
- STTK 398.2K
- Earning Date
- DSP 08-11-2025
- STTK 07-31-2025
- Dividend Yield
- DSP N/A
- STTK N/A
- EPS Growth
- DSP N/A
- STTK N/A
- EPS
- DSP 0.13
- STTK N/A
- Revenue
- DSP $306,484,000.00
- STTK $4,606,000.00
- Revenue This Year
- DSP $18.36
- STTK N/A
- Revenue Next Year
- DSP $15.95
- STTK N/A
- P/E Ratio
- DSP $102.81
- STTK N/A
- Revenue Growth
- DSP 30.64
- STTK 69.65
- 52 Week Low
- DSP $8.70
- STTK $0.69
- 52 Week High
- DSP $26.33
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- DSP 48.13
- STTK 40.01
- Support Level
- DSP $12.79
- STTK $0.77
- Resistance Level
- DSP $13.72
- STTK $0.91
- Average True Range (ATR)
- DSP 0.61
- STTK 0.08
- MACD
- DSP 0.05
- STTK -0.03
- Stochastic Oscillator
- DSP 71.13
- STTK 19.95
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.